Landmark Statin Trials Across the Spectrum of Risk: Secondary Stroke Prevention

Slide lecture program (12 slides): View & Download

1. Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
2. SPARCL Trial of Secondary StrokePrevention: Study Design
3. SPARCL Primary End Point: Time to Fatal or Nonfatal Stroke
4. SPARCL Secondary End Point:Time to Major Coronary Event
5. SPARCL: Benefit/Risk
6. Effect of Atorvastatin on Stroke In SPARCL Patients with Diabetes
7. SPARCL: Stroke in Patients With Carotid Stenosis
8. SPARCL: Carotid Endarterectomy inPatients with Carotid Stenosis
9. SPARCL: Prespecified andPost-Hoc Analyses
10. SPARCL: Ischemic and Hemorrhagic Stroke Post hoc Analysis
11. SPARCL: Multivariable Cox RegressionModel Baseline Characteristics

Click on slides to preview

Download slides below

634918764299517500-Download slides CV risk and lipid management. section 5 (PPTX 553KB)

Landmark Statin Trials Across the Spectrum of Risk	Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
SPARCL Trial of Secondary StrokePrevention: Study Design	SPARCL Primary End Point: Time to Fatal or Nonfatal Stroke
SPARCL Secondary End Point:Time to Major Coronary Event	SPARCL: Benefit/Risk
Effect of Atorvastatin on Stroke In SPARCL Patients with Diabetes	SPARCL: Stroke in Patients With Carotid Stenosis
SPARCL: Carotid Endarterectomy inPatients with Carotid Stenosis	SPARCL: Prespecified andPost-Hoc Analyses
SPARCL: Ischemic and Hemorrhagic Stroke Post hoc Analysis	SPARCL: Multivariable Cox RegressionModel Baseline Characteristics